Palbociclib Efficient in Patients with Hormone-Resistant Breast Cancer

Palbociclib Efficient in Patients with Hormone-Resistant Breast Cancer
drugsEncouraging results from a Phase II clinical trial of Palbociclib for the treatment of advanced breast cancer patients were published this month in Clinical Cancer Research Palbociclib is an experimental oral drug that functions by inhibiting the cyclin-dependent kinase (CDK4/6), a key cell cycle protein involved in the transition G1-S phase, which is frequently dysregulated in breast cancer. The CDK4/6 kinase was shown to be responsible for the phosphorylation of retinoblastoma (Rb) protein, which plays a crucial role in the negative control of the cell cycle and in tumor progression. In their study “CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment," the research team tested palbociclib (PD0332991) in patients with advanced breast cancer positive for retinoblastoma (Rb) protein and with measurable disease. The patients had been previously submitted to several chemotherapy and hormonal regimens for metastatic disease. Palbociclib was given at 125 mg orally on days 1 to 21 on a cycle of 28 days. The drug was well tolerated and there was prolonged progression-free survival (PFS) i
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.